Please confirm that your email address is correct, so you can successfully receive this alert.
The authors report no financial relationships with commercial interests. The opinions expressed in this letter do not reflect those of the Department of Defense or the United States Air Force.
This letter was accepted for publication in May 2011.
Copyright © American Psychiatric Association
To the Editor: Cetirizine is approved by the U.S. Food and Drug Administration (FDA) for allergic rhinitis in all age groups (1). Published reports have described cetirizine-induced dystonic reactions in the pediatric patient population and in one adult (2—4). We present the case of an adult who developed involuntary movements associated with cetirizine use and discontinuation.
A 24-year-old Caucasian woman presented to the local hospital emergency department with a nose laceration she sustained from walking into a glass window after acute alcohol intoxication (her blood alcohol level was 140 mg/dL). She reported taking 10 mg/day of cetirizine for 3 months, daily valacyclovir (for herpes simplex virus 1), and depot medroxyprogesterone. She denied a history of medication side effects, denied taking more than the recommended dosage, and was not taking over-the-counter or herbal products. She denied a history of head injuries, seizures, or loss of consciousness, and she also denied treatment with psychotropic medications. Initially, results from her physical examination were unremarkable with the exception of a superficial laceration on her nose. The results of laboratory testing, including thyroid-stimulating hormone and urine toxicology, were all within normal limits or negative.
While in the emergency department, the patient developed acute involuntary "bizarre grimacing" and dysarthria. There was no evidence of oculogyric crisis, torticollis, tongue protrusions, opisthotonos, gait disturbances, or weakness in her extremities. She did not lose consciousness, and results of her neurological examination were negative. She was given intravenous diphenhydramine (50 mg), benztropine (2 mg), and lorazepam (2 mg). Neuroimaging results of her head and spine were negative, and her dystonia had resolved by the time a neurologist arrived at her bedside.
A follow-up call 1 month later revealed that the patient had stopped taking cetirizine after she was discharged from the emergency department. She reported facial twitching on the day after discharge. Over the course of the month, she experienced two episodes of difficulty walking, hand "discoordination," and "muscle jerks of her throat." These episodes lasted approximately 20 minutes. An outpatient neurology consultation was arranged at the time of the call, but it is not known whether she kept that appointment.
Cetirizine is a carboxylated metabolite of hydroxyzine (a piperazine histamine H1 receptor antagonist) (1). Piperazines have central dopamine D2 receptor blockade (5). Cetirizine's large size, lipophobic nature, and greater affinity for peripheral H1 receptors are believed to reduce CNS penetration and central side effects (2). However, one positron emission tomography study of cetirizine revealed approximately 30% H1 receptor binding in the cerebral cortex (1, 2). Cetirizine has negligible anticholinergic activity (6). We speculate that as a piperazine derivative, cetirizine blocked the striatal D2 receptors and resulted in an acute dystonic reaction in our patient. In addition, we also speculate that our patient's 3-month cetirizine use resulted in D2 receptor hypersensitivity similar to that observed in long-term antipsychotic use, with subsequent involuntary movements after its discontinuation. It is also possible that her cetirizine use and the subsequent development of involuntary movements are independent events. More research is needed to clarify cetirizine's effect on central D2 receptors.
Download citation file:
Web of Science® Times Cited: 1